Plain-English translation of NCT06482554 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing lumateperone, a newer medication, to see if it can help improve motivation and drive in people living with schizophrenia or related psychotic disorders. Many people with these conditions struggle with apathy—a feeling of low motivation and lack of drive—even when their other symptoms improve. The study wants to find out whether this medication can specifically help with that motivation problem.
While current treatments can help with hallucinations and delusions, many people still struggle with low motivation and drive. This trial is testing whether the new treatment can fill that gap and help people feel more motivated and engaged in daily life.
You likely qualify if…
You likely don't qualify if…
You would take either the new medication or a capsule form of your current medication once daily for 8 weeks. During this time, you'll have visits where the research team will assess your motivation levels and other symptoms using questionnaires and rating scales. You'll also need to pass a drug screening test at the start to make sure your symptoms aren't caused by other substances.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States